topSkip to main content

Menu, Secondary

Menu Trigger

Menu

National Institutes of Health

Biomedical research funded by the National Institutes of Health (NIH) and performed at research universities helps assure U.S. leadership in the life sciences revolution of the 21st Century. Putting NIH on a sustained pathway to restore its purchasing power after a decade worth of loss to inflation and budget cuts is critical to sustaining the extraordinary progress in the improvement of human health of the past decades. Investment in NIH will continue to create jobs and strengthen the workforce, improve the lives—and quality of life—of millions of current and future patients, and help assure continuing U.S. economic and national security.

Sustained investment in biotechnology and genomics is crucial to the development of novel therapies for diseases, including: cancer, Alzheimer's, autism, and diabetes. The NIH also responds rapidly to public health emergencies and in support of biodefense, such as in the case of Ebola, Zika, and COVID-19.

 

A statement by AAU President Mary Sue Coleman on Senate passage today of the FY17 continuing resolution, which includes significant funding for the National Institutes of Health pursuant to the 21st Century Cures Act.
AAU urges Congress to pass the 21st Century Cures Act during its current session.
The House and Senate’s bipartisan efforts on such legislation in the 114th Congress have been truly extraordinary and should not go unfulfilled.
This letter is about OMB's FY2018 budget materials and guidance for the next administration which highlights the importance of providing robust investment in higher education and scientific research.
AAU, APLU and COGR comment to Carrie D. Wolinetz, National Institutes of Health, on Federal Register Document number 2016-18601.
AAU, APLU, COGR letter on proposed changes to NIH guidelines for human stem cell research and consideration of certain human-animal chimera research.
AAU today stated its strong support for the restoration of the year-round Pell Grant for low-income families and additional funding for the NIH contained in the Senate FY17 Labor-HHS-Education appropriations bill.
The undersigned scientific and professional societies, higher education associations, universities, and research institutions are writing to express their opposition to a provision in the Commercializing on Small Business Innovation Act of 2016 (HR 4783) which would increase the SBIR set-aside from 3.46 percent in fiscal year (FY) 2018 to 4.5 percent in FY 2022 of any federal agency budget that provides more than $100 million for research.